MilliporeSigma, the US and Canadian life science business of Merck KGaA, has acquired Erbi Biosystems, a Massachusetts-based developer of a 2 ml micro-bioreactor technology dubbed the Breez platform.
The deal aims to strengthen MilliporeSigma’s position in the production of therapeutic proteins allowing for bioreactor processes from 2 ml to 2000...
